Oncolytics Biotech, Inc. Common Shares (ONCY) Stock Price

ONCYStock

$0.86+12.82%52W

Market Cap$109.84M

P/E—

PEG Ratio—

Div yield—

Beta0.84

ONCY Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-7.63%

Price vs S&P 500 (4W)-4.18%

VGM Score42.08

Book Value / Share (Quarterly)$0.05

P/TBV (Annual)7.04x

Cash Flow / Share (Quarterly)$-0.18

Price vs S&P 500 (YTD)2.79%

EPS (TTM)$-0.27

10-Day Avg Trading Volume0.12M

EPS Excl Extra (TTM)$-0.27

EPS (Annual)$-0.30

ROI (Annual)-449.98%

Cash / Share (Quarterly)$0.12

ROA (Last FY)-157.08%

EBITD / Share (TTM)$-0.27

ROE (5Y Avg)-177.65%

Cash Flow / Share (Annual)$-0.25

P/B Ratio20.70x

P/B Ratio (Quarterly)15.17x

Net Income / Employee (Annual)$-790,049

Net Interest Coverage (TTM)-1311.50x

ROA (TTM)-144.60%

EPS Incl Extra (Annual)$-0.30

Current Ratio (Annual)2.82x

Quick Ratio (Quarterly)2.40x

3-Month Avg Trading Volume0.12M

52-Week Price Return12.82%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.99

P/S Ratio (Annual)406.54x

Asset Turnover (Annual)0.01x

52-Week High$1.04

EPS Excl Extra (Annual)$-0.30

CapEx CAGR (5Y)88.66%

Tangible BV CAGR (5Y)-14.52%

26-Week Price Return-6.78%

Quick Ratio (Annual)2.54x

13-Week Price Return-31.03%

Total Debt / Equity (Annual)0.18x

Current Ratio (Quarterly)2.88x

Enterprise Value$88.77M

Book Value / Share Growth (5Y)-26.82%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-1206.45%

Cash / Share (Annual)$0.15

3-Month Return Std Dev74.15%

Net Income / Employee (TTM)$-757,751

ROE (Last FY)-530.00%

Net Interest Coverage (Annual)-33.16x

EPS Basic Excl Extra (Annual)$-0.30

Total Debt / Equity (Quarterly)0.15x

EPS Incl Extra (TTM)$-0.27

Receivables Turnover (Annual)0.00x

ROI (TTM)-384.49%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.45

Price vs S&P 500 (52W)14.17%

Year-to-Date Return3.65%

5-Day Price Return0.00%

EPS Normalized (Annual)$-0.30

ROA (5Y Avg)-83.59%

Net Profit Margin (Annual)-1164.52%

Month-to-Date Return3.65%

Cash Flow / Share (TTM)$-0.36

EBITD / Share (Annual)$-0.33

Operating Margin (Annual)-1206.45%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-160.53%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.27

P/TBV (Quarterly)21.79x

P/B Ratio (Annual)17.13x

Book Value / Share (Annual)$0.05

Price vs S&P 500 (13W)-31.95%

Beta0.84x

Revenue / Share (TTM)$0.00

ROE (TTM)-440.39%

52-Week Low$0.96

mGradeC

vgmGradeC

ONCY Earnings Surprise History

Q2 25-0.05est. -0.06

Q3 25-0.10est. -0.05

Q1 26-0.08est. -0.05

Q2 26-0.08est. -0.05

ONCY Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.88

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
ONCYOncolytics Biotech, Inc. Common Shares	—	—	C	$0.86
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Oncolytics Biotech, Inc. Common Shares

Oncolytics Biotech is a clinical-stage biopharmaceutical company developing immunotherapies for cancer. Its lead candidate, pelareorep, enhances immune response to make tumors more susceptible to existing oncology treatments. The company's pipeline includes programs targeting breast cancer and gastrointestinal cancers across multiple indications.